Abstract
The advent of molecularly targeted agents has brought major breakthroughs in oncology. However, because these drugs are expensive and financial resources are limited, attention to their cost-effectiveness is rapidly increasing. It seems that establishment of cost-effectiveness is complex but is determined for the most part by the cost of drug acquisition and the drug's efficacy. This article examines the cost-effectiveness of molecularly targeted drugs.
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 136-138 |
| Number of pages | 3 |
| Journal | Clinical Pharmacology & Therapeutics |
| Volume | 85 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2009 |
Research programs
- EMC MM-03-86-01
- EMC MM-03-86-08